^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CLN-619

i
Other names: CLN-619, CLN 619, CLN619
Associations
Company:
Cullinan Therap
Drug class:
γδ TCR modulator, MICA agonist, MICB agonist, NKG2D stimulant
Associations
3ms
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=30, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
CLN-619
7ms
New P1 trial
|
CLN-619
7ms
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=410, Recruiting, Cullinan Oncology Inc. | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab) • CLN-619
almost2years
Enrollment change • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab) • CLN-619
2years
CLN-619, a clinical-stage MICA/B-specific IgG1 antibody which restores the MICA/B-NKG2D axis requires Fc function for potent anti-tumor activity (SITC 2022)
Treatment was administered 2X weekly for four weeks intraperitoneal. Statistics were analyzed by one-way ANOVA adjusted for multiple comparisons.
Clinical
|
MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
|
CLN-619
over2years
CLN-619, a clinical-stage MICA/MICB-specific IgG1 antibody, restores the MICA/MICB-NKG2D axis to promote NK-mediated tumor cell lysis (AACR 2022)
Given the pan-cancer expression of MICA/MICB in both solid and hematological malignancies, CLN-619 is expected to have broad anti-tumor activity. CLN-619 is currently being investigated in a Phase 1 clinical trial for the treatment of patients with advanced solid tumors.
Clinical
|
MICA (MHC Class I Polypeptide-Related Sequence A) • MICB (MHC Class I Polypeptide-Related Sequence B) • NKG2D (killer cell lectin like receptor K1)
|
CLN-619